HRAS recombinant protein

HRAS Protein, Human, Recombinant (His Tag)

Cat. Num. AAA258004

• Gene Names: HRAS; CTLO; HAMSV; HRAS1; K-RAS; N-RAS; RASH1; C-H-RAS; H-RASIDX; C-BAS/HAS; C-HA-RAS1
• Purity: >94% as determined by SDS-PAGE
• Synonyms: HRAS; N/A; HRAS Protein, Human, Recombinant (His Tag); Human HRAS/GTPase Hras Protein (His Tag); C-BAS/HAS Protein, Human; C-H-RAS Protein, Human; C-HA-RAS1 Protein, Human; CTLO Protein, Human; H-RASIDX Protein, Human; HAMSV Protein, Human; HRAS1 Protein, Human; p21ras Protein, Human; RASH1 Protein, Human; Harvey rat sarcoma viral oncogene homolog; HRAS recombinant protein

• Host: Baculovirus-Insect Cells
• Purity/Purification: >94% as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile 50mM Tris, 100mM NaCl, pH8.0, 10% gly. Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.

• Species: Human
• Endotoxin: <1.0EU per ug of the protein as determined by the LAL method
• Predicted N Terminal: Met 1
• Tag: C-His
• Protein Construction: A DNA sequence encoding the human HRAS (P01112)(Met 1-Cys 186) was fused with a polyhistidine tag at the C-terminus.
• Reconstitution: It is recommended that the sterile water (400ul) be added to the vial to prepare a stock solution of 0.25mg/mL. Concentration is measured by UV.
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -20°C to -80°C upon receipt. Recommend to aliquot the protein into samller quantities for optimal storage. Avoid repeated freeze-thaw cycles.

SDS-PAGE

Related Product Information for HRAS recombinant protein

Background: HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family, and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is a rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin, and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Defects in HRAS are the cause of oral squamous cell carcinoma.

Product Categories/Family for HRAS recombinant protein

EGFR Signaling Pathway

References

Schulten HJ, et al. (2011) Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res. 31(12):4179-83.
Gripp KW, et al. (2011) Molecular confirmation of HRAS p.G12S in siblings with Costello syndrome. Am J Med Genet A. 155A(9):2263-8.
Na KY, et al. (2012) Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer. J Surg Oncol. 105(1):10-4.
Membrino A, et al. (2011) G4-DNA formation in the HRAS promoter and rational design of decoy oligonucleotides for cancer therapy. PLoS One. 6(9):e24421.

NCBI and Uniprot Product Information

• NCBI GI #: 190938
• NCBI GeneID: 3265
• UniProt Accession #: P01112; Q14080; Q6FHV9; Q9BR65; Q9UCE2; B5BUA0
• Molecular Weight: The recombinant human HRAS consists of 197 amino acids and predicts a molecular mass of 22.45 kDa. It migrates as an approximately 23 kDa band in SDS-PAGE in SDS-PAGE under reducing conditions.
• NCBI Official Full Name: ras protein, partial
• NCBI Official Synonym Full Names: Harvey rat sarcoma viral oncogene homolog
• NCBI Official Symbol: HRAS
• NCBI Official Synonym Symbols: CTLO; HAMSV; HRAS1; K-RAS; N-RAS; RASH1; C-H-RAS; H-RASIDX; C-BAS/HAS; C-HA-RAS1
• NCBI Protein Information: GTPase HRas; p21ras; H-Ras-1; p19 H-RasIDX protein; c-has/bas p21 protein; transforming protein p21; Ha-Ras1 proto-oncoprotein; c-ras-Ki-2 activated oncogene; GTP- and GDP-binding peptide B; transformation gene: oncogene HAMSV; Ras family small GTP bindin
• UniProt Protein Name: GTPase HRas
• UniProt Gene Name: HRAS
• UniProt Synonym Gene Names: HRAS1
• UniProt Entry Name: RASH_HUMAN